These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 22685175)

  • 1. Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia.
    Tasian SK; Doral MY; Borowitz MJ; Wood BL; Chen IM; Harvey RC; Gastier-Foster JM; Willman CL; Hunger SP; Mullighan CG; Loh ML
    Blood; 2012 Jul; 120(4):833-42. PubMed ID: 22685175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel xenograft model to study the role of TSLP-induced CRLF2 signals in normal and malignant human B lymphopoiesis.
    Francis OL; Milford TA; Martinez SR; Baez I; Coats JS; Mayagoitia K; Concepcion KR; Ginelli E; Beldiman C; Benitez A; Weldon AJ; Arogyaswamy K; Shiraz P; Fisher R; Morris CL; Zhang XB; Filippov V; Van Handel B; Ge Z; Song C; Dovat S; Su RJ; Payne KJ
    Haematologica; 2016 Apr; 101(4):417-26. PubMed ID: 26611474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TSLP as a Potential Therapy in the Treatment of CRLF2 B Cell Acute Lymphoblastic Leukemia.
    Alkashgari HR; Ruiz-Jimenez C; Stoian C; Coats JS; Baez I; Chirshev E; Martinez SR; Dovat S; Francis-Boyle OL; Casiano CA; Payne KJ
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting TSLP-Induced Tyrosine Kinase Signaling Pathways in
    Sia KCS; Zhong L; Mayoh C; Norris MD; Haber M; Marshall GM; Raftery MJ; Lock RB
    Mol Cancer Res; 2020 Dec; 18(12):1767-1776. PubMed ID: 32801162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia.
    Maude SL; Tasian SK; Vincent T; Hall JW; Sheen C; Roberts KG; Seif AE; Barrett DM; Chen IM; Collins JR; Mullighan CG; Hunger SP; Harvey RC; Willman CL; Fridman JS; Loh ML; Grupp SA; Teachey DT
    Blood; 2012 Oct; 120(17):3510-8. PubMed ID: 22955920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential efficacy and prognosis of silencing the CRLF2‑mediated AKT/mTOR pathway in pediatric acute B‑cell lymphoblastic leukemia.
    Jiang M; Zou X; Lu L
    Oncol Rep; 2019 Feb; 41(2):885-894. PubMed ID: 30535452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in signaling through the B-cell leukemia oncoprotein CRLF2 in response to TSLP and through mutant JAK2.
    van Bodegom D; Zhong J; Kopp N; Dutta C; Kim MS; Bird L; Weigert O; Tyner J; Pandey A; Yoda A; Weinstock DM
    Blood; 2012 Oct; 120(14):2853-63. PubMed ID: 22915648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL.
    Savino AM; Sarno J; Trentin L; Vieri M; Fazio G; Bardini M; Bugarin C; Fossati G; Davis KL; Gaipa G; Izraeli S; Meyer LH; Nolan GP; Biondi A; Te Kronnie G; Palmi C; Cazzaniga G
    Leukemia; 2017 Nov; 31(11):2365-2375. PubMed ID: 28331226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRLF2-Positive B-Cell Acute Lymphoblastic Leukemia in Adult Patients: A Single-Institution Experience.
    Konoplev S; Lu X; Konopleva M; Jain N; Ouyang J; Goswami M; Roberts KG; Valentine M; Mullighan CG; Bueso-Ramos C; Zweidler-McKay PA; Jorgensen JL; Wang SA
    Am J Clin Pathol; 2017 Apr; 147(4):357-363. PubMed ID: 28340183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thymic stromal-derived lymphopoietin induces proliferation of pre-B leukemia and antagonizes mTOR inhibitors, suggesting a role for interleukin-7Ralpha signaling.
    Brown VI; Hulitt J; Fish J; Sheen C; Bruno M; Xu Q; Carroll M; Fang J; Teachey D; Grupp SA
    Cancer Res; 2007 Oct; 67(20):9963-70. PubMed ID: 17942929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LNK/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitors.
    Cheng Y; Chikwava K; Wu C; Zhang H; Bhagat A; Pei D; Choi JK; Tong W
    J Clin Invest; 2016 Apr; 126(4):1267-81. PubMed ID: 26974155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome.
    Schwartzman O; Savino AM; Gombert M; Palmi C; Cario G; Schrappe M; Eckert C; von Stackelberg A; Huang JY; Hameiri-Grossman M; Avigad S; Te Kronnie G; Geron I; Birger Y; Rein A; Zarfati G; Fischer U; Mukamel Z; Stanulla M; Biondi A; Cazzaniga G; Vetere A; Wagner BK; Chen Z; Chen SJ; Tanay A; Borkhardt A; Izraeli S
    Proc Natl Acad Sci U S A; 2017 May; 114(20):E4030-E4039. PubMed ID: 28461505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.
    Tasian SK; Teachey DT; Li Y; Shen F; Harvey RC; Chen IM; Ryan T; Vincent TL; Willman CL; Perl AE; Hunger SP; Loh ML; Carroll M; Grupp SA
    Blood; 2017 Jan; 129(2):177-187. PubMed ID: 27777238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia.
    Ott CJ; Kopp N; Bird L; Paranal RM; Qi J; Bowman T; Rodig SJ; Kung AL; Bradner JE; Weinstock DM
    Blood; 2012 Oct; 120(14):2843-52. PubMed ID: 22904298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A recombinant antibody fragment directed to the thymic stromal lymphopoietin receptor (CRLF2) efficiently targets pediatric Philadelphia chromosome-like acute lymphoblastic leukemia.
    Mohamed SMA; Wohlmann A; Schofield P; Sia KCS; McCalmont H; Savvides SN; Verstraete K; Kavallaris M; Christ D; Friedrich KH; Bayat N; Lock RB
    Int J Biol Macromol; 2021 Nov; 190():214-223. PubMed ID: 34481852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.
    Yoda A; Yoda Y; Chiaretti S; Bar-Natan M; Mani K; Rodig SJ; West N; Xiao Y; Brown JR; Mitsiades C; Sattler M; Kutok JL; DeAngelo DJ; Wadleigh M; Piciocchi A; Dal Cin P; Bradner JE; Griffin JD; Anderson KC; Stone RM; Ritz J; Foà R; Aster JC; Frank DA; Weinstock DM
    Proc Natl Acad Sci U S A; 2010 Jan; 107(1):252-7. PubMed ID: 20018760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL.
    Hurtz C; Wertheim GB; Loftus JP; Blumenthal D; Lehman A; Li Y; Bagashev A; Manning B; Cummins KD; Burkhardt JK; Perl AE; Carroll M; Tasian SK
    J Clin Invest; 2020 Jul; 130(7):3637-3653. PubMed ID: 32191635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRLF2 and IKZF1 abnormalities in Mexican children with acute lymphoblastic leukemia and recurrent gene fusions: exploring surrogate markers of signaling pathways.
    Moreno Lorenzana D; Juárez Velázquez MDR; Reyes León A; Martínez Anaya D; Hernández Monterde A; Salas Labadía C; Navarrete Meneses MDP; Zapata Tarrés M; Juárez Villegas L; Jarquín Ramírez B; Cárdenas Cardós R; Herrera Almanza M; Paredes Aguilera R; Pérez Vera P
    J Pathol Clin Res; 2021 Jul; 7(4):410-421. PubMed ID: 33890726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRLF2 rearrangement in Ph-like acute lymphoblastic leukemia predicts relative glucocorticoid resistance that is overcome with MEK or Akt inhibition.
    Meyer LK; Delgado-Martin C; Maude SL; Shannon KM; Teachey DT; Hermiston ML
    PLoS One; 2019; 14(7):e0220026. PubMed ID: 31318944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding the biology of CRLF2-overexpressing acute lymphoblastic leukemia.
    Tasian SK; Loh ML
    Crit Rev Oncog; 2011; 16(1-2):13-24. PubMed ID: 22150304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.